Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations

被引:0
作者
Jaya Singh
Nishita Thota
Suhasini Singh
Shila Padhi
Puja Mohan
Shivani Deshwal
Soumit Sur
Mithua Ghosh
Amit Agarwal
Ramesh Sarin
Rosina Ahmed
Sachin Almel
Basumita Chakraborti
Vinod Raina
Praveen K. DadiReddy
B. K. Smruti
Senthil Rajappa
Chandragouda Dodagoudar
Shyam Aggarwal
Manish Singhal
Ashish Joshi
Rajeev Kumar
Ajai Kumar
Deepak K. Mishra
Neeraj Arora
Aarati Karaba
Satish Sankaran
Shanmukh Katragadda
Arunabha Ghosh
Vamsi Veeramachaneni
Ramesh Hariharan
Ashraf U. Mannan
机构
[1] Strand Center for Genomics and Personalized Medicine,Department of Computer Science and Automation
[2] Strand Life Sciences,undefined
[3] Triesta Sciences,undefined
[4] Health Care Global Enterprises Limited,undefined
[5] BLK Super Specialty Hospital,undefined
[6] Indraprastha Apollo Hospitals,undefined
[7] Tata Medical Center,undefined
[8] P. D. Hinduja Hospital and Medical Research Centre,undefined
[9] Fortis Healthcare,undefined
[10] Continental Hospitals,undefined
[11] Bombay Hospital and Medical Research Centre,undefined
[12] Basavatarakam Indo American Cancer Hospital and Research Institute,undefined
[13] Sir Ganga Ram Hospital,undefined
[14] Nanavati Super Specialty Hospital,undefined
[15] Rajiv Gandhi Cancer Institute and Research Centre,undefined
[16] Health Care Global Enterprises Limited,undefined
[17] Indian Institute of Science,undefined
来源
Breast Cancer Research and Treatment | 2018年 / 170卷
关键词
Breast cancer; Next-generation sequencing; Multi-gene panel;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:189 / 196
页数:7
相关论文
共 84 条
[1]  
Antoniou A(2003)Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 1117-1130
[2]  
Pharoah PDP(2007)Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 1329-1333
[3]  
Narod S(2015)A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients J Mol Diagn 17 533-544
[4]  
Chen S(2015)Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment JAMA Oncol 1 943-951
[5]  
Parmigiani G(2017)A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes Cancer 123 1721-1730
[6]  
Lincoln SE(2017)The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: what are the implications for the management of patients and families? Oncotarget 8 1957-1971
[7]  
Kobayashi Y(2014)Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes Eur J Hum Genet 22 1305-1313
[8]  
Anderson MJ(2016)Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer J Clin Oncol 34 1460-1468
[9]  
Desmond A(2017)Associations between cancer predisposition testing panel genes and breast cancer JAMA Oncol 18 823-832
[10]  
Kurian AW(2016)Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing Genet Med 18 1-8